Objective: The role of neutrophil gelatinase-associated lipocalin (NGAL) for the evaluation of renal function in chronic kidney disease (CKD) has not yet to be determined. We aimed to perform a meta-analysis exploring the correlation between NGAL and glomerular filtration rate (GFR) in CKD patients, and to further identify factors affecting NGAL's performance. Results: Neutrophil gelatinase-associated lipocalin showed a strong negative correlation with measured glomerular filtration rate (mGFR). The pooled correlation coefficient (r) with corresponding 95% confidence intervals for the correlation between serum NGAL (sNGAL) and GFR was −0.48, meanwhile that for urine NGAL (uNGAL) and GFR was −0.34. However, NGAL's performance is different in subgroups restricted by clinical settings, race, sex, age, and staging of renal function.
have focused on finding new potential biomarkers for detecting early kidney damage.
Neutrophil gelatinase-associated lipocalin (NGAL), a ubiquitous 25-kDa lipocalin iron-carrying protein, 10 was originally isolated from neutrophils. 11 Then people found that it also expressed in tissues such as kidney, liver, epithelial cells, 12, 13 and vascular cells in atherosclerotic plaques. 14 It attracted the attention of clinical scientists for it was found to be one of the earliest, most robustly induced genes and proteins in the tubular epithelium of the distal nephron and it was released from tubular epithelial cells following tissue damage, such as ischemic renal injury. 15 Further studies were carried out on multiple molecular forms in urine. In contrast to the dimeric form produced by neutrophils, the monomeric form originates from kidney tubular epithelial cells. 16 This difference has the potential to improve the specificity of NGAL as a renal biomarker.
NGAL has been identified as an early biomarker of acute kidney injury (AKI). 15, [17] [18] [19] [20] [21] [22] [23] AKI is increasingly recognized as a prelude to CKD. In an experimental study in rats, ongoing inflammation and immune activity were found to be involved with the pathogenesis of CKD, and NGAL was upregulated, suggesting that it may be a valuable biomarker for the development of CKD after AKI. 24, 25 NGAL has recently been proven useful to quantitate CKD. 26 Thus, there has been interest in NGAL as an additional measure of kidney impairment in CKD.
Baseline serum NGAL (sNGAL) and urine NGAL (uNGAL) were well correlated with residual GFR in CKD and have been shown to be excellent indicators of renal function in patients affected by autosomal dominant polycystic kidney disease. 27 In a cross-sectional study performed on 80 nondiabetic patients with CKD Stages 2-4, sNGAL rose gradually, reaching a higher value in Stage 4 CKD, and was related to measured glomerular filtration rate (mGFR). 28 A prospective cohort trial of 96 patients with CKD has shown that baseline sNGAL and uNGAL were predictors of mGFR decline. 29 Another study of children with CKD proved the significant correlations between sNGAL and uNGAL and mGFR. 30 Since then, concerns focused on NGAL for CKD prediction have been accelerating.
However, Liu et al 31 conclude that uNGAL levels do not improve risk prediction of progressive CKD. A study with type 2 diabetic patients showed that of the urinary tubular markers, NGAL was not significantly increased in the early stage of diabetic nephropathy with normoalbuminuria and microalbuminuria. 32 Another cross-sectional study with type 1 diabetic patients revealed no correlation between uNGAL level and GFR. 33 A matched case-control study showed that with adjustment for urinary creatinine and albumin concentration, the association between NGAL and incident CKD stage was not significant. 34 Another study of 140 diabetic nephropathy patients also showed that unlike sNGAL, the uNGAL level did not change significantly throughout the varying degrees of CKD and lacked clinical value in predicting the GFR decline rate. 35 Based on these controversial results, we conducted the present meta-analysis to investigate the evaluation value of sNGAL and uNGAL for GFR decline in CKD, respectively, and to further identify which factors affect its performance.
| METHODS

| Data sources and search strategy
In accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines, 36 we searched PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to November 2017. The following terms were used: CKD, chronic kidney disease, chronic renal failure, chronic renal insufficiency, chronic renal dysfunction, and neutrophil gelatinase-associated lipocalin. References of the selected studies were further screened manually to identify whether additional eligible articles were available or not.
| Study selection
The inclusion criteria of this study were composed of the following characteristics: (a) investigation of the relationship between NGAL and eGFR/mGFR; (b) randomized controlled trial; (c) original data of We investigated the methodological quality of the present study using the second version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). 37 The QUADAS-2 assesses the risk of bias and applicability in four domains: (a) patient selection (consecutive or random sample enrolled, case-control design, and inap- 
| Statistical analysis
After appropriate conversion, data from the various studies were combined using random effects meta-analyses. 38 The heterogeneity of the r values between studies was determined by calculating the Q statistic, derived from the chi-square test, and the inconsistency index (I   2   ) . 39, 40 A P value < 0.05 or an I 2 value >50% suggested heterogeneity. 41 If notable heterogeneity was detected, a sensitivity analysis was performed for all studies to further investigate the study heterogeneity.
In a subgroup analysis, studies were stratified by the following: 
| Subject characteristics and quality assessment
The main characteristics of the included studies are summarized in 
| Evaluation value of NGAL for GFR in CKD
The pooled correlation coefficient (r) with corresponding 95% confi- notable heterogeneity (P = 0.14, I 2 = 49%; Figure 6 ).
| Influence factors affecting NGAL of CKD
The pooled r values estimated for the different subgroups are presented in Tables 2 and 3, based 
| Publication bias
Begg's funnel plot proved that there was no evidence of notable publication bias of the included studies (Figures 7 and 8 ).
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| DISCUSSION
We performed a systematic review and meta-analysis to clarify the correlation between NGAL and GFR in CKD patients and to investigate whether NGAL could be identified as a maker for kidney function in CKD. As tubular epithelial cells play a crucial role in the pathogenesis of CKD progression, the tubular injury marker NGAL is expected to be useful in reflecting disease activity and kidney function. Many studies showed that urinary and serum NGAL could be biological makers for disease activity and kidney function:
immunoglobulin A nephropathy, 64 glomerulonephritis, 65 pediatric lupus nephritis, 66 children with CKD, 67 diabetic nephropathy, 68 and drug-induced chronic tubulointerstitial nephritis. 45 However, discrepancies between several recent prospective studies have resulted in controversy regarding the potential clinical value of uNGAL for CKD. [29] [30] [31] [32] [33] [34] [35] So far, there have been no specific assays assessing the discriminative value of the two markers in CKD patients. Whether both sNGAL and uNGAL could be satisfactory markers of CKD is still 2. Kidney aging presents as global glomerulosclerosis and subsequent interstitial fibrosis. Decreasing podocyte density and total numbers are also associated with aging. 69 Aging has been reported to be an independent risk of acute on chronic renal failure, and recovery from AKI decreases with aging. Older individuals show a lower rate of full recovery than younger counterparts after acute on chronic renal failure. 79 3. Sex is an important influencing factor for susceptibility to AKI and young females exhibit the lowest incidence. 71 Many studies report that differences in sex may influence the susceptibility, progression, and response to AKI and/or to treatment. 72 Evidence shows male sex to be an important risk factor 73 and proves higher susceptibility to cisplatin-induced nephrotoxicity than that in females. 74 In contrast, the incidence of AKI in women is lower than that in men. Why do the two NGAL markers present discriminative values in CKD? It is likely due to the following factors:
1. NGAL exists in three main forms: monomer, homodimer, and NGAL/MMP-9 complex. 77 The monomer form of NGAL is predominantly released by tubular cells, whereas the homodimer form is mainly released from neutrophils. 78, 79 Therefore, different forms may be specific for the different function and causes of CKD. 2. The uNGAL consists of more complex forms, originally secreted from neutrophils and excreted by the renal epithelium of distal tubules respectively. [11] [12] [13] 16 3. Theoretically, a serum sample is more stable than urine, as the latter has various influencing factors, such as urinary output, timing of sampling collection, and storage temperature.
For all meta-analyses, heterogeneity is a potential problem when interpreting the results. Heterogeneity is one limitation of this research across all included studies of uNGAL and sNGAL (I 2 = 88% and 83%, respectively). However, heterogeneity was inevitable because these studies were based on different institutions and settings worldwide. In these included studies, the NGAL was not assessed by the same assay of NGAL concentration examination.
Some different kits for measuring urinary NGAL from multiple companies, such as Abbott or Bioport, were used in the cited reports.
However, standard substance of NGAL is not determined between the kits.
Another limitation of this study is the assays used to evaluate GFR. Inulin clearance and nuclear medicine techniques, such as 99 Tc-DTPA or 51 Cr-EDTA, are considered as the gold standards to define CKD. However, these methods cannot be used routinely in clinical practice because they are invasive and time-consuming.
In conclusion, despite the limitations of our meta-analysis, all currently available evidence supports a strong negative correlation between NGAL and GFR in CKD patients, particularly in Stages 3-5.
Several factors should be considered on the sampling choice, from blood or urine. More multicenter randomized controlled trials are needed to further investigate the accuracy of NGAL. 
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